86results about How to "Induce immune response" patented technology

Described are methods for inducing both a mucosal and a systemic immune response in the respiratory, digestive or urogenital tracts of a mammal to a microbial pathogen. The methods comprise topically administering onto the sublingual mucosa of the mammal an amount of an antigen effective to induce the mucosal and systemic immune responses and a pharmaceutically acceptable carrier or diluent. Pharmaceutical formulations and dosage forms for immunizing a mammal against a microbial pathogen to elicit a mucosal and systemic immune response in the respiratory, digestive or urogenital tracts are also described.

Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and / or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and / or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and / or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases.

The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.

The invention discloses a tumor cell membrane coated nanometer material, a method for preparing the same and application of the tumor cell membrane coated nanometer material, and belongs to the fieldof nanometer materials. The tumor cell membrane coated nanometer material is particularly a tumor site targeting bionic nanometer material. Cancer cell membranes are coated on the surfaces of mesoporous silicon dioxide nanometer particles (MSN), and glucose oxidase (GOx) is loaded on the MSN, so that hunger treatment can be carried out. The tumor cell membrane coated nanometer material, the methodand the application have the advantages that the surfaces of bionic materials are functionalized, CMSN-GOx has immune escape and homologous targeting capability, and accordingly enrichment of nanometer particles on tumor sites can be obviously improved; tumor can be partially ablated by the prepared CMSN-GOx nanometer particles, and certain antitumor immune response can be generated by means of tumor membrane induction; the tumor can be effectively ablated by the aid of hunger therapy by the CMSN-GOx combined with PD-1 immunotherapy as compared with injection of only PD-1 immunosupressant orthe CMSN-GOx, and adaptive immune response can be induced; the tumor cell membrane coated nanometer material is excellent in biocompatibility and has great clinical application potential.

Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and / or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and / or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and / or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases.

Provided is a novel vaccine for preventing COVID-19, the nucleotide sequence of an antigen of the novel vaccine is SEQ NO: 1, the amino acid sequence of the antigen of the novel vaccine is SEQ NO: 2,and the antigen of the vaccine comprises two functional parts: an S protein receptor binding structural domain capable of inducing a specific neutralizing antibody and a T cell related N protein truncated peptide fragment capable of inducing and activating effector T cells; The vaccine disclosed by the invention has the characteristics that the T cell related N protein truncated peptide fragment has weak capability of inducing the generation of the N protein antibody, so that a vaccine inoculator and a COVID-19 infected patient can be identified by using the N protein antibody, and the vaccineantigen does not induce the generation of the N protein antibody, so that lung injuries can be reduced, and the vaccine is safer. The cell vaccine disclosed by the invention is low in manufacturing cost, and can induce generation of virus-specific neutralizing antibodies and T cell immune response.

A harmless cancer vaccine is made from cancer cells with extracellular proteins including self-recognition molecular patterns being digested by a proteinase. The cancer vaccine is used to vaccinate an individual to induce immune responses against cancer cells systemically. Cancer cells become harmless when they are digested by Tumorase™. Some proteinases including trypsin cannot kill cancer cells completely and treated cancer cells need to be further processed in order to be harmless and effective. Cancer cells may be from tissue-cultured human or animal cancer cell lines or cancer patients directly. Cancer vaccine vaccinated individuals produce cancer vaccine specific immune responses against cancer cells. Immune response components may be isolated and used to fight against cancer for a cancer patient with a suppressed immune system. Cancer vaccine specific immune components may include cancer vaccine specific polyclonal antibodies, B-cells, T-cells, natural killer cells, monocytes, macrophages and other lymphocytes.

The invention relates to immunogenic compositions and to methods for immunizing animals using the same. The immunogenic composition comprises a lipid formulation most usually in solid form, and at least one immunogenic component. A preferred immunogenic component is a living organism. In a preferred embodiment the composition is formulated for oral administration.

Described is a replication-competent virus capable of replication and having lytic capacity in target cells. The virus comprises in the genome thereof, at least one DNA sequence coding for a silencing factor functional in reducing expression of a target gene in the target cells, operably linked to one or more expression control sequences, functional in the target cells. The use thereof in the preparation of a medicament and the use thereof in a method for lysing target cells expressing a virus inhibitory factor are also described.

Described is a replication competent recombinant virus, being capable to replicate and having lytic capacity in target cells, the said cell being hampered in the p53 dependent apoptosis pathway, the virus including in the genome thereof, the coding sequence of at least one restoring factor functional in restoring the p53 apoptosis pathway in the said target cells, operably linked to one or more expression control sequences, functional in the said target cells, as well as the use thereof in the preparation of a medicament, in particular for suppressing uncontrolled cell growth.

The present invention relates to compositions and methods useful for treating a cancer in mammals, including humans. The methods and compositions typically comprise use of a chemotherapeutic agent and a γδ T cell activator such that the composition is effective for treating a cancer. Preferably the composition enhances the effect of the γδ T cell activator and / or prevents or delays the escape of a tumor from control chemotherapy, particularly an anti-angiogenic chemotherapeutic agent.

Porcine pestivirus designated herein as atypical porcine pestivirus (“APPV”) (Genbank accession no. KR011347.1). Immunogenic compositions to induce an immune response against porcine pestivirus infection in a pig are described, which APPV antigenic agents (e.g., isolated whole virus, derivatives thereof, functional fragments thereof, and combinations of the foregoing). Methods of vaccinating against porcine pestivirus infection using the immunogenic compositions are also described. The methods can be also applied for clinical research and / or study, including diagnostic methods for detecting pestivirus infection using monoclonal antibodies specifically binding to APPV epitopes.

The present invention relates to an immuno-therapeutic and prophylactic vaccine comprising monocytes or immature myeloid cells (IMCs) loaded with the ligand of natural killer T cell and an antigen for the prevention and treatment of infectious disease or cancer, more precisely, an immuno-therapeutic and prophylactic vaccine comprising monocytes or IMCs loaded with α-galactosylceramide (αGalCer), a kind of glycolipid and a natural killer T cell ligand, and antigen. Monocytes or immature myeloid cells (IMCs) therein, which are easily obtainable, unlike dendritic cells, not only induce a significant level of cytotoxic T lymphocyte responses but also have a prophylactic and therapeutic effect on malignant tumor. Therefore, the immuno-therapeutic and prophylactic vaccine of the present invention can be effectively used as an immunotherapeutic agent.

The invention provides application of S. pneumoniae protein to resisting infection of S. pneumoniae. The endopeptidase O (PepO) of S. pneumoniae is a subcutaneous immunologic adjuvant, and the prepared S. pneumoniae protein vaccines have the good protection effects on resisting infection of S. pneumoniae through mixing and fusing expression of the subcutaneous immunologic adjuvant and 673rd to 863rd amino acid peptide fragment of zinc metal protease B (ZmpB).

A cell for immunotherapy of the present invention includes a nucleic acid encoding a Wilms tumor 1 gene product or a fragment of the Wilms tumor 1 gene product, wherein the nucleic acid including (i) a region encoding a fragment of the Wilms tumor 1 gene product, the fragment being indicated by positions 194 to 493 of amino acid sequence of SEQ ID NO:1 or by positions corresponding to the positions 194 to 493 of amino acid sequence corresponding to SEQ ID NO:1 and (ii) only one AUG as a functional start codon, connected to a 5′ terminal side of the region via 3m (m is 124-192) bases intervening between the AUG as the functional start codon and the 5′ terminal side of the region, and a nucleic acid encoding CD1d, wherein the cell has been loaded with a glycolipid recognized by antigen receptor of NKT cell.

The invention provides a method for the treatment of a patient having a more severe form of Alzheimer's disease (AD), where the severe form of AD is characterized by pathogenic deposits of amyloid beta peptide (Aβ), comprising the administration of an immunogenic fragment of Aβ capable of inducing an immune response in the form of antibodies to specific to the pathogenic deposits of Aβ and, in particular, to neurotoxic forms of Aβ including N-terminally truncated forms of Aβ. The invention further provides a method for selecting a suitable immunogenic fragment of Aβ for the treatment of a more severe form of AD.

The invention provides rBCG for expression of Br. Melitensis P39 and L7 / L12 fusion gene. The rBCG is constructed by transferring an expression vector carrying codon-optimized Br. Melitensis P39 and L7 / L12 fusion gene into BCG. Brucellosis-generated cytoplasm binding protein PBP39 (coding gene is P39) and Brucellosis ribosomal protein L7 / L12 are both T-cell antigen. Bacillus Calmette-Guerin (BCG) vaccine is the only one commercial vaccine for preventing tuberculosis so far. The BCG vaccine has a remarkable immunologic adjuvant effect and is an exogenous gene expression host with good performance and high safety. By BCG expression of the codon-optimized Brucellosis P39 and L7 / L12 fusion gene, expression quantity of the target gene can be increased. The rBCG vaccine can simulate intracellur infection and parasitic characteristics of Brucellosis to more effectively induce body to generate immune response, can perform advantages of high safety, simple preparation, low cost, etc. of BCG as the expression host as well as the immunologic adjuvant effect of the BCG itself, and is expected to become a novel Brucellosis vaccine.

A pneumococcal vaccine comprising a fusion protein at least comprising a full-length family 1 pneumococcal surface protein A (PspA) or a fragment thereof, and a full-length family 2 PspA or a fragment thereof, in particular any one of the following fusion proteins (1) to (3):(1) a fusion protein at least comprising a family 1, clade 2 PspA and a family 2, clade 3 PspA,(2) a fusion protein at least comprising a family 1, clade 2 PspA and a family 2, clade 4 PspA, and(3) a fusion protein at least comprising a family 1, clade 2 PspA and a family 2, clade 5 PspA,is useful as a pneumococcal vaccine comprising a single protein antigen that has broadly cross-reactive immunogenicity and can induce immune response against a wide range of pneumococcal clinical isolates.

The present invention provides an adjuvant for vaccine including a Dectin-1 ligand and a TLR agonist, a vaccine including the adjuvant for vaccine and at least one antigen, and the like.

The present invention relates to methods of inducing an immune response to cytomegalovirus (CMV) using a genetically modified CMV that is conditionally replication defective. The methods of the invention can be used to treat and / or prevent primary CMV infection, infection due to reactivation of a latent CMV and a super-infection of a different strain of CMV that had been previously encountered. The present invention also relates to a replication defective CMV which has been recombinantly altered to allow for external control of viral replication. Compositions comprising the replication defective CMV are also encompassed by the present invention.

Viruses having an impaired ability to deISGylate ISG15 conjugates, in particular, viral mutants comprising a mutation in the viral genome that reduces or eliminates the ability of the viral OTU domain-containing protein encoded by the viral genome to deISGylate ISG15 conjugates and / or deubiquitinate ubiquitinated proteins and / or deNeddylate Neddylated proteins are disclosed. Such viral mutants may be used in the formulation of immunogenic compositions for inducing an immune response and preventing, managing and / or treating a viral infection. Also disclosed are methods for identifying anti-viral compounds, in particular, methods of identifying compounds that reduce or inhibit the deISGylation activity and / or deubiquitination and / or deNeddylation activity of a viral OTU domain-containing protein. The compounds identified using such methods may be used as antiviral agents for the prevention, treatment and / or management of viral infections.

The present invention is generally related to virus-like particles (VLPs) comprising rabies virus (RV) glycoproteins (G proteins) and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and / or prevention of rabies virus infection.

The present invention relates to an immuno-therapeutic and prophylactic vaccine comprising monocytes or immature myeloid cells (IMCs) loaded with the ligand of natural killer T cell and an antigen for the prevention and treatment of infectious disease or cancer, more precisely, an immuno-therapeutic and prophylactic vaccine comprising monocytes or IMCs loaded with α-galactosylceramide (αGalCer), a kind of glycolipid and a natural killer T cell ligand, and antigen. Monocytes or immature myeloid cells (IMCs) therein, which are easily obtainable, unlike dendritic cells, not only induce a significant level of cytotoxic T lymphocyte responses but also have a prophylactic and therapeutic effect on malignant tumor. Therefore, the immuno-therapeutic and prophylactic vaccine of the present invention can be effectively used as an immunotherapeutic agent.

Synthetic HIV envelope proteins, vectors and compositions thereof, and methods for inducing protective immunity against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in vaccines to provide improved protective immunity against HIV.

The present invention relates to methods of inducing an immune response to cytomegalovirus (CMV) using a genetically modified CMV that is conditionally replication defective. The methods of the invention can be used to treat and / or prevent primary CMV infection, infection due to reactivation of a latent CMV and a super-infection of a different strain of CMV that had been previously encountered. The present invention also relates to a replication defective CMV which has been recombinantly altered to allow for external control of viral replication. Compositions comprising the replication defective CMV are also encompassed by the present invention.

The invention provides preparation and application of a Her2-neu antigen positive tumor therapeutic vaccine, and particularly provides a fusion protein. The fusion protein contains (a) a tumor antigen Her2-neu extracellular region element and (b) a heat shock protein element. The invention also provides a dendritic cell sensitized by fusion protein and a corresponding tumor therapeutic vaccine. Test proves Her2-neu antigen specific immunological response can be effectively activated by applying the vaccine in vivo, and the vaccine is effectively applied to Her2-neu positive tumor.

The present invention is related with the isolation and cloning of a new gene, the production of the protein encoded by this gene by using recombinant systems, and the use of this antigen in a vaccine formulation as a purified protein and / or naked DNA, to induce an immune response in aquatic organisms against different ectoparasite species, including the known as sea lice, and pathogens associated with these infestations. The vaccine preparations, administered by oral route, immersion bath or injection, demonstrated its efficacy by producing IgM humoral immune response and reducing the number of parasites per fish in the vaccinated fishes.

Disclosed are nanoparticles that are introduced into cells and express a specific protein and a manufacturing method thereof. More particularly, the present invention relates to mRNA nanoparticles, which increase the expression of a specific protein capable of stimulating the cellular immune system to induce cellular immune responses and are thus applicable to treat a variety of diseases, do not require passage across the nuclear envelope because a desired gene is delivered not as plasmid DNA itself but in the form of mRNA, thus improving the efficiency of protein expression, and the nanoparticles are generated through a one-step process with a relatively small amount of plasmid DNA via rolling circle transcription (RCT), thereby providing a simple and economical process for gene delivery. The present invention is also concerned with such mRNA nanoparticles.